Nuo Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|
| Revenue | $721.0K | $11.5M | $7.8M | $11.6M | $10.6M | $7.2M | $3.9M |
| Cost of Revenue | $1.1M | $8.0M | $6.8M | $8.5M | $3.9M | $2.7M | $1.6M |
| Gross Profit | $-370.0K | $3.5M | $991.2K | $3.1M | $6.6M | $4.5M | $2.3M |
| Gross Margin | -51.3% | 30.8% | 12.8% | 26.9% | 62.9% | 62.4% | 58.8% |
| Operating Expenses | |||||||
| Research & Development | $1.3M | $2.6M | $4.0M | $3.8M | $3.4M | $98.1K | $415.6K |
| SG&A Expense | $3.8M | $9.0M | $9.9M | $6.8M | $5.6M | $2.9M | $2.6M |
| Operating Income | $-15.5M | $-41.3M | $-23.4M | $-18.1M | $-12.9M | $-3.5M | $-5.4M |
| Operating Margin | -2,154.4% | -359.0% | -301.4% | -156.4% | -122.1% | -48.5% | -138.1% |
| Interest Expense | $10.8K | — | — | — | — | — | — |
| Pretax Income | $-15.0M | $-52.9M | $-18.9M | $-20.2M | $-19.8M | $-3.5M | $-6.8M |
| Income Tax Expense | — | $-89.0K | $19.6K | $18.6K | $18.0K | $18.0K | $14.0K |
| Net Income | $-15.0M | $-52.8M | $-18.9M | $-20.2M | $-19.8M | $-3.5M | $-6.8M |
| Net Margin | -2,077.4% | -458.8% | -243.3% | -175.0% | -187.4% | -48.4% | -174.3% |
| EPS (Basic) | $-1.02 | $-0.42 | $-0.16 | $-0.20 | $-0.24 | $-0.08 | $-0.23 |
| EPS (Diluted) | $-1.02 | $-0.42 | $-0.16 | $-0.20 | $-0.24 | $-0.08 | $-0.23 |
| Shares Outstanding (Basic) | 14.6M | 125.7M | 125.7M | 107.2M | 93.8M | 55.5M | 44.1M |
| Shares Outstanding (Diluted) | 14.6M | 125.7M | 125.7M | 107.2M | 93.8M | 55.5M | 44.1M |
| Dividends Per Share | — | — | — | — | — | — | — |